Integrated Approach for the Diagnosis of Shiga Toxin-Producing Escherichia coli Infections in Humans.


Journal

Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969

Informations de publication

Date de publication:
2021
Historique:
entrez: 11 3 2021
pubmed: 12 3 2021
medline: 2 4 2021
Statut: ppublish

Résumé

Shiga toxin-producing Escherichia coli (STEC) are human pathogens causing severe diseases, such as hemorrhagic colitis and the hemolytic uremic syndrome. The prompt diagnosis of STEC infection is of primary importance to drive the most appropriate patient's management procedures. The methods to diagnose STEC infections include both direct isolation of the STEC from stool samples and the identification of indirect evidences based on molecular, phenotypic, and serological applications. Here, the procedures in use at the Italian Reference Laboratory for E. coli infections are described.

Identifiants

pubmed: 33704747
doi: 10.1007/978-1-0716-1339-9_1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-17

Références

Petruzziello-Pellegrini TN, Marsden PA (2012) Shiga toxin-associated hemolytic uremic syndrome: advances in pathogenesis and therapeutics. Curr Opin Nephrol Hypertens 21(4):433–440. https://doi.org/10.1097/MNH.0b013e328354a62e
doi: 10.1097/MNH.0b013e328354a62e pubmed: 22660553 pmcid: 5303627
Noris M, Remuzzi G (2005) Hemolytic uremic syndrome. J Am Soc Nephrol 16(4):1035–1050. https://doi.org/10.1681/ASN.2004100861
doi: 10.1681/ASN.2004100861 pubmed: 15728781
Jacquinet S, De Rauw K, Pierard D, Godefroid N, Collard L, Van Hoeck K, Sabbe M (2018) Haemolytic uremic syndrome surveillance in children less than 15 years in Belgium, 2009-2015. Arch Public Health 76:41. https://doi.org/10.1186/s13690-018-0289-x
doi: 10.1186/s13690-018-0289-x pubmed: 30128150 pmcid: 6091157
Loirat C, Saland J, Bitzan M (2012) Management of hemolytic uremic syndrome. Presse Med 41(3 Pt 2):e115–e135. https://doi.org/10.1016/j.lpm.2011.11.013
doi: 10.1016/j.lpm.2011.11.013 pubmed: 22284541
Freedman SB, Xie J, Neufeld MS, Hamilton WL, Hartling L, Tarr PI, Nettel-Aguirre A, Chuck A, Lee B, Johnson D, Currie G, Talbot J, Jiang J, Dickinson J, Kellner J, MacDonald J, Svenson L, Chui L, Louie M, Lavoie M, Eltorki M, Vanderkooi O, Tellier R, Ali S, Drews S, Graham T, Pang XL, (APPETITE) APPEIT (2016) Shiga toxin-producing Escherichia coli infection, antibiotics, and risk of developing hemolytic uremic syndrome: a meta-analysis. Clin Infect Dis 62(10):1251–1258. https://doi.org/10.1093/cid/ciw099
doi: 10.1093/cid/ciw099 pubmed: 26917812 pmcid: 4845788
Kakoullis L, Papachristodoulou E, Chra P, Panos G (2019) Shiga toxin-induced haemolytic uraemic syndrome and the role of antibiotics: a global overview. J Infect 79(2):75–94. https://doi.org/10.1016/j.jinf.2019.05.018
doi: 10.1016/j.jinf.2019.05.018 pubmed: 31150744
Safdar N, Said A, Gangnon RE, Maki DG (2002) Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA 288(8):996–1001. https://doi.org/10.1001/jama.288.8.996
doi: 10.1001/jama.288.8.996 pubmed: 12190370
Agger M, Scheutz F, Villumsen S, Mølbak K, Petersen AM (2015) Antibiotic treatment of verocytotoxin-producing Escherichia coli (VTEC) infection: a systematic review and a proposal. J Antimicrob Chemother 70(9):2440–2446. https://doi.org/10.1093/jac/dkv162
doi: 10.1093/jac/dkv162 pubmed: 26093376
Ardissino G, Tel F, Possenti I, Testa S, Consonni D, Paglialonga F, Salardi S, Borsa-Ghiringhelli N, Salice P, Tedeschi S, Castorina P, Colombo RM, Arghittu M, Daprai L, Monzani A, Tozzoli R, Brigotti M, Torresani E (2016) Early volume expansion and outcomes of hemolytic uremic syndrome. Pediatrics 137(1). https://doi.org/10.1542/peds.2015-2153
Scheutz F, Teel LD, Beutin L, Piérard D, Buvens G, Karch H, Mellmann A, Caprioli A, Tozzoli R, Morabito S, Strockbine NA, Melton-Celsa AR, Sanchez M, Persson S, O’Brien AD (2012) Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stx nomenclature. J Clin Microbiol 50(9):2951–2963. https://doi.org/10.1128/JCM.00860-12
doi: 10.1128/JCM.00860-12 pubmed: 22760050 pmcid: 3421821
Friedrich AW, Bielaszewska M, Zhang WL, Pulz M, Kuczius T, Ammon A, Karch H (2002) Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J Infect Dis 185(1):74–84. https://doi.org/10.1086/338115
doi: 10.1086/338115 pubmed: 11756984
Melton-Celsa AR, O’Brien AD (2014) New therapeutic developments against Shiga toxin-producing Escherichia coli. Microbiol Spectr 2(5). https://doi.org/10.1128/microbiolspec.EHEC-0013-2013
EFSA (2009) Technical specifications for the monitoring and reporting of verotoxigenic Escherichia coli (VTEC) on animals and food (VTEC surveys on animals and food) on request of EFSA. EFSA J 7(11):1366
doi: 10.2903/j.efsa.2009.1366
EFSA BIOHAZ Panel, Koutsoumanis K, Allende A, Alvarez-Ordonez A, Bover-Cid S, Chemaly M, Davies R, De Cesare A, Herman L, Hilbert F, Lindqvist R, Nauta M, Peixe L, Ru G, Simmons M, Skandamis P, Suffredini E, Jenkins C, Monteiro Pires S, Morabito S, Nauta M, Niskanen T, Scheutz F, daSilva FM, Messens W, Bolton D (2020) Scientific opinion on the pathogenicity assessment of Shiga toxin-producing Escherichia coli (STEC) and the public health risk posed by contamination of food with STEC. EFSA J 18(1):5967
doi: 10.2903/j.efsa.2020.5967
Grande L, Michelacci V, Bondì R, Gigliucci F, Franz E, Badouei MA, Schlager S, Minelli F, Tozzoli R, Caprioli A, Morabito S (2016) Whole-genome characterization and strain comparison of VT2f-producing Escherichia coli causing hemolytic uremic syndrome. Emerg Infect Dis 22(12):2078–2086. https://doi.org/10.3201/eid2212.160017
doi: 10.3201/eid2212.160017 pubmed: 27584691 pmcid: 5189129
Fricker M, Messelhäusser U, Busch U, Scherer S, Ehling-Schulz M (2007) Diagnostic real-time PCR assays for the detection of emetic Bacillus cereus strains in foods and recent food-borne outbreaks. Appl Environ Microbiol 73(6):1892–1898. https://doi.org/10.1128/AEM.02219-06
doi: 10.1128/AEM.02219-06 pubmed: 17259359 pmcid: 1828801
Perelle S, Dilasser F, Grout J, Fach P (2004) Detection by 5′ nuclease PCR of Shiga-toxin producing Escherichia coli O26, O55, O91, O103, O111, O113, O145 and O157:H7, associated with the world’s most frequent clinical cases. Mol Cell Probes 18(3):185–192. https://doi.org/10.1016/j.mcp.2003.12.004
doi: 10.1016/j.mcp.2003.12.004 pubmed: 15135453
Nielsen EM, Andersen MT (2003) Detection and characterization of verocytotoxin-producing Escherichia coli by automated 5′ nuclease PCR assay. J Clin Microbiol 41(7):2884–2893. https://doi.org/10.1128/jcm.41.7.2884-2893.2003
doi: 10.1128/jcm.41.7.2884-2893.2003 pubmed: 12843017 pmcid: 165313
Perelle S, Dilasser F, Grout J, Fach P (2005) Detection of Escherichia coli serogroup O103 by real-time polymerase chain reaction. J Appl Microbiol 98(5):1162–1168. https://doi.org/10.1111/j.1365-2672.2005.02545.x
doi: 10.1111/j.1365-2672.2005.02545.x pubmed: 15836486

Auteurs

Stefano Morabito (S)

Istituto Superiore di Sanità, Rome, Italy.

Fabio Minelli (F)

Istituto Superiore di Sanità, Rome, Italy.

Rosangela Tozzoli (R)

Istituto Superiore di Sanità, Rome, Italy. rosangela.tozzoli@iss.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH